Search results
Two Biosimilars Approved in Europe for Autoimmune Disorders
Medscape· 2 days agoThe drugs are intended to treat several types of arthritis, psoriasis, COVID-19, and Crohn's...
Arthritis Medications: NSAIDs, Steroids, Narcotics, Topical Treatments, and More
WebMD· 2 days agoThere are dozens of medications available with or without a prescription to treat the various forms of arthritis. Nonsteroidal anti-inflammatory drugs or ...
AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop
Barrons.com· 1 day agoAbbVie raised its full-year earnings outlook despite continuing sales declines for autoimmune drug...
Four NHS signs in the leg of deadly blood clot - get help ‘now’
Daily Express· 6 days agoBlood clots can be "life threatening" if not spotted and dealt with "quickly", the NHS says.
Parotitis (Parotid Gland Swelling)
Health via Yahoo News· 7 hours agoParotitis is inflammation of one or both parotid salivary glands. Symptoms include pain, swelling, and sore throat. Treatment may depend on severity and...
What Is Amyloidosis?
Health via Yahoo News· 3 days agoAL amyloidosis can affect several organs in your body and is more common in adults over the age of 65. AA amyloidosis: This type of amyloidosis occurs as...
Microscopic Colitis
Health via Yahoo News· 2 days agoPeople with certain autoimmune disorders, diseases where the immune system attacks healthy tissue, may be likelier to have intestinal inflammation....
FDA Roundup: April 26, 2024
NBC 17 Raleigh· 1 day agoBiosimilars are now approved for 15 different reference biologics, and treat illnesses like rheumatoid arthritis, inflammatory bowel ...
Drug distributor Cardinal Health to lose OptumRx contracts
Reuters via AOL· 5 days agoCardinal Health said on Monday its contracts with UnitedHealth Group's OptumRx, one of its largest...
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed...
Benzinga· 3 days agoThe confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid
